Neoadjuvant chemotherapy and short-term morbidity in patients undergoing mastectomy with and without breast reconstruction

JAMA Surgery

Volumn 149, Issue 10, 2014, Pages 1068-1076

  Abt, Nicholas B ^a   Flores, José M ^b   Baltodano, Pablo A ^a   Sarhane, Karim A ^a   Abreu, Francis M ^b   Cooney, Carisa M ^a   Manahan, Michele A ^a   Stearns, Vered ^a   Makary, Martin A ^a   Rosson, Gedge D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; BREAST RECONSTRUCTION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MIDDLE AGED; MORBIDITY; PRIVATE HOSPITAL; TISSUE EXPANDER; TOTAL QUALITY MANAGEMENT; UNIVERSITY HOSPITAL; BREAST NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MAMMAPLASTY; MASTECTOMY; MIDDLE AGED; MORBIDITY; NEOADJUVANT THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84908275279     PISSN: 21686254     EISSN: 21686262     Source Type: Journal    
DOI: 10.1001/jamasurg.2014.1076     Document Type: Article

References (33)

1. Kaufmann M, vonMinckwitz G, Bear HD, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 2007;18(12):1927-1934.
2. Waljee JF, Newman LA. Neoadjuvant systemic therapy and the surgical management of breast cancer. Surg Clin North Am. 2007;87(2):399-415, ix.
3. SchaverienMV, Munnoch DA. Effect of neoadjuvant chemotherapy on outcomes of immediate free autologous breast reconstruction. Eur J Surg Oncol. 2013;39(5):430-436.
4. Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JP. Multiple-treatmentsmeta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst. 2008;100(24): 1780-1791.
5. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 2008;26(5): 778-785.
6. Azzawi K, Ismail A, Earl H, Forouhi P, Malata CM. Influence of neoadjuvant chemotherapy on outcomes of immediate breast reconstruction. Plast Reconstr Surg. 2010;126(1):1-11.
7. Broadwater JR, Edwards MJ, Kuglen C, Hortobagyi GN, Ames FC, Balch CM. Mastectomy following preoperative chemotherapy: strict operative criteria control operative morbidity. Ann Surg. 1991;213(2):126-129.
8. Hu YY,Weeks CM, In H, et al. Impact of neoadjuvant chemotherapy on breast reconstruction. Cancer. 2011;117(13):2833-2841.
9. Warren Peled A, Itakura K, Foster RD, et al. Impact of chemotherapy on postoperative complications after mastectomy and immediate breast reconstruction. Arch Surg. 2010;145(9):880-885.
10. Glasgow MA, YuH, Rutherford TJ, et al. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV). J Surg Oncol. 2013;107(2):195-200.
11. Wolf PS, Park JO, Bao F, et al. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. J AmColl Surg. 2013;216(1):41-49.
12. Liao Y, Yang ZL, Peng JS, Xiang J,Wang JP. Neoadjuvant chemotherapy for gastric cancer: ameta-analysis of randomized, controlled trials. J Gastroenterol Hepatol. 2013;28(5):777-782.
13. American College of Surgeons National Surgical Quality Improvement Program. Surgical quality improvement. http://site.acsnsqip.org. Accessed January 10, 2013.
14. Khuri SF, HendersonWG, Daley J, et al; Principal Investigators of the Patient Safety in Surgery Study. Successful implementation of the Department of Veterans Affairs' National Surgical Quality Improvement program in the private sector: the patient safety in surgery study. Ann Surg. 2008;248 (2):329-336.
15. Sarhane KA, Flores JM, Cooney CM, et al. Preoperative anemia and postoperative outcomes in immediate breast reconstructive surgery: a critical analysis of 10,958 patients from the ACS-NSQIP database. Plast Reconst Surg Glob Open. 2013;1:e30.
16. Smith BL. Neoadjuvant versus adjuvant systemic therapy for operable breast cancer: equivalent outcomes? Ann Surg. 2013;257(2):180-181.
17. Smith I, Chua S. Medical treatment of early breast cancer, IV: neoadjuvant treatment. BMJ. 2006;332(7535):223-224.
18. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19(22):4224-4237.
19. Eng MK, Bernstein AJ, Katz MH, Shikanov S, Zorn KC, Shalhav AL. Impact of renal lesion size on perioperative and pathologic outcomes in patients undergoing laparoscopic partial nephrectomy. J Endourol. 2009;23(3):439-443.
20. Hanwright PJ, Davila AA,Mioton LM, Fine NA, Bilimoria KY, Kim JY. A predictive model of risk and outcomes in tissue expander reconstruction: a multivariate analysis of 9786 patients. J Plast Surg Hand Surg. 2013;47(6):513-518.
21. Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev. 2007;(2):CD005002.
22. Vandeweyer E, Hertens D, Nogaret JM, Deraemaecker R. Immediate breast reconstruction with saline-filled implants: no interference with the oncologic outcome? Plast Reconstr Surg. 2001;107 (6):1409-1412.
23. Patani N, Devalia H, Anderson A, Mokbel K. Oncological safety and patient satisfaction with skin-sparing mastectomy and immediate breast reconstruction. Surg Oncol. 2008;17(2):97-105.
24. Mittendorf EA, Buchholz TA, Tucker SL, et al. Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy. Ann Surg. 2013;257(2):173-179.
25. Decker MR, Greenblatt DY, Havlena J, Wilke LG, Greenberg CC, Neuman HB. Impact of neoadjuvant chemotherapy on wound complications after breast surgery. Surgery. 2012;152(3):382-388.
26. Selber JC, Kurichi JE, Vega SJ, Sonnad SS, Serletti JM. Risk factors and complications in free TRAM flap breast reconstruction. Ann Plast Surg. 2006;56(5):492-497.
27. Mehrara BJ, Santoro TD, Arcilla E,Watson JP, ShawWW, Da Lio AL. Complications after microvascular breast reconstruction: experience with 1195 flaps. Plast Reconstr Surg. 2006;118(5): 1100-1111.
28. Oh E, Chim H, Soltanian HT. The effects of neoadjuvant and adjuvant chemotherapy on the surgical outcomes of breast reconstruction. J Plast Reconstr Aesthet Surg. 2012;65(10):e267-e280.
29. Centers for Disease Control and Prevention. July 2013 CDC/NHSN protocol clarifications. http://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef-current.pdf. Accessed August 14, 2013.
30. Loibl S, vonMinckwitz G, Raab G, et al. Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial. Ann Surg Oncol. 2006;13(11):1434-1442.
31. Gouy S, Rouzier R, Missana MC, Atallah D, Youssef O, Barreau-Pouhaer L. Immediate reconstruction after neoadjuvant chemotherapy: effect on adjuvant treatment starting and survival. Ann Surg Oncol. 2005;12(2):161-166.
32. Cordeiro PG,McCarthy CM. A single surgeon's 12-year experience with tissue expander/implant breast reconstruction, part I: a prospective analysis of early complications. Plast Reconstr Surg. 2006; 118(4):825-831.
33. Singh N, Reaven NL, Funk SE. Immediate 1-stage vs. tissue expander postmastectomy implant breast reconstructions: a retrospective real-world comparison over 18 months. J Plast Reconstr Aesthet Surg. 2012;65(7):917-923.